To investigate these evasion mechanisms, in collaboration with Johnson and Balko, we recently performed transcriptome profiling and tissue staining of patients who developed resistance to PD-1 immunotherapy in melanoma, non-small cell lung cancer (NSCLC), and TNBC (18). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.